The Manufacturers Life Insurance Company Purchases New Holdings in Agilent Technologies, Inc. $A

The Manufacturers Life Insurance Company purchased a new position in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 163,805 shares of the medical research company's stock, valued at approximately $21,758,000. The Manufacturers Life Insurance Company owned approximately 0.06% of Agilent Technologies at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Fiduciary Trust Co raised its stake in Agilent Technologies by 1.6% in the third quarter. Fiduciary Trust Co now owns 4,931 shares of the medical research company's stock valued at $633,000 after purchasing an additional 77 shares in the last quarter. Sapient Capital LLC increased its holdings in Agilent Technologies by 4.2% in the 1st quarter. Sapient Capital LLC now owns 2,105 shares of the medical research company's stock valued at $240,000 after buying an additional 85 shares during the period. Plan A Wealth LLC increased its holdings in Agilent Technologies by 3.2% in the 4th quarter. Plan A Wealth LLC now owns 2,959 shares of the medical research company's stock valued at $403,000 after buying an additional 92 shares during the period. UNIVEST FINANCIAL Corp raised its position in shares of Agilent Technologies by 1.3% in the 2nd quarter. UNIVEST FINANCIAL Corp now owns 7,145 shares of the medical research company's stock valued at $949,000 after buying an additional 93 shares in the last quarter. Finally, IHT Wealth Management LLC raised its position in shares of Agilent Technologies by 4.9% in the 4th quarter. IHT Wealth Management LLC now owns 2,041 shares of the medical research company's stock valued at $278,000 after buying an additional 96 shares in the last quarter.

Agilent Technologies Stock Performance

NYSE A opened at $157.60 on Friday. The firm's fifty day moving average price is $139.76 and its two-hundred day moving average price is $126.85. The stock has a market cap of $44.51 billion, a PE ratio of 31.02, a PEG ratio of 2.74 and a beta of 1.25. Agilent Technologies, Inc. has a fifty-two week low of $108.35 and a fifty-two week high of $163.75. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.62 and a current ratio of 2.10.

Agilent Technologies (NYSE:A - Get Free Report) last announced its quarterly earnings results on Wednesday, August 26th. The medical research company reported $1.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.49 by $0.13. Agilent Technologies had a net margin of 19.53% and a return on equity of 24.84%. The company had revenue of $1.88 billion during the quarter, compared to the consensus estimate of $1.84 billion. During the same period in the prior year, the business earned $1.37 earnings per share. The company's revenue for the quarter was up 8.1% compared to the same quarter last year. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. On average, equities analysts expect that Agilent Technologies, Inc. will post 6.05 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently issued reports on A shares. Jefferies Financial Group initiated coverage on shares of Agilent Technologies in a research report on Thursday, July 9th. They set a "hold" rating and a $135.00 price target on the stock. HSBC reduced their target price on Agilent Technologies from $180.00 to $165.00 and set a "buy" rating on the stock in a report on Wednesday, June 3rd. Morgan Stanley lifted their price target on Agilent Technologies from $160.00 to $175.00 and gave the company an "overweight" rating in a research note on Wednesday, August 12th. JPMorgan Chase & Co. upped their price objective on Agilent Technologies from $180.00 to $190.00 and gave the stock an "overweight" rating in a research report on Thursday. Finally, Bank of America raised their price objective on Agilent Technologies from $155.00 to $180.00 and gave the company a "buy" rating in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $170.33.

Agilent Technologies News Roundup

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Agilent reported fiscal Q3 revenue of $1.88 billion, up 8.1% year over year and ahead of the $1.84 billion consensus estimate. Adjusted EPS was $1.62, beating expectations of approximately $1.49 and rising from $1.37 a year earlier. Operating profit, cash flow and margins also improved. Agilent Reports Third-Quarter Fiscal Year 2026 Financial Results
• Positive Sentiment: The company raised its fiscal 2026 outlook to adjusted EPS of $6.18-$6.21, above the $6.06 analyst consensus, and projected approximately $7.5 billion in revenue versus expectations of $7.4 billion. Management cited improving demand for laboratory instruments used in research and drug development. Agilent raises annual profit forecast on improving lab tools demand
• Positive Sentiment: Analyst sentiment strengthened significantly following the results. Citigroup and JPMorgan raised their price targets to $190, while RBC lifted its target to $185. Barclays, Stifel, Goldman Sachs, Bank of America, TD Cowen and Bernstein also raised targets, with most assigning Buy, Overweight or Outperform ratings. The revised targets imply roughly 11%-21% potential upside from the referenced trading level. Analyst price-target revisions
• Neutral Sentiment: Agilent is trading near its 52-week high and above both its 50-day and 200-day moving averages. That momentum supports investor confidence, although the stock’s valuation—around 32 times earnings and a PEG ratio above 2.7—leaves less room for disappointment.
• Neutral Sentiment: Institutional positioning was mixed in the latest filings: 594 investors added shares while 550 reduced holdings. Significant purchases by FMR, JPMorgan, Bank of New York Mellon and T. Rowe Price were offset by large sales from several other institutions.

Agilent Technologies Profile

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company's product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source